The value of MRD as a marker for disease eradication in AML [Video]

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the value of measurable residual disease (MRD) as a marker for disease eradication and a predictor of treatment outcomes in acute myeloid leukemia (AML). He mentions the QuANTUM-First trial (NCT02668653), which provides evidence for the value of FLT3-ITD-specific MRD in predicting treatment outcomes, as well as the BMT CTN 0901 study (NCT01339910). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.